Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference Read more about Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing Read more about Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing Larimar Therapeutics Announces $95 Million Private Placement Financing Read more about Larimar Therapeutics Announces $95 Million Private Placement Financing Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia Read more about Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia Read more about Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results Read more about Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results Read more about Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference Read more about Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference Larimar Therapeutics Added to NASDAQ Biotechnology Index Read more about Larimar Therapeutics Added to NASDAQ Biotechnology Index Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update Read more about Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last » Subscribe to
Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference Read more about Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing Read more about Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
Larimar Therapeutics Announces $95 Million Private Placement Financing Read more about Larimar Therapeutics Announces $95 Million Private Placement Financing
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia Read more about Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia Read more about Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results Read more about Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results Read more about Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference Read more about Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Larimar Therapeutics Added to NASDAQ Biotechnology Index Read more about Larimar Therapeutics Added to NASDAQ Biotechnology Index
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update Read more about Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update